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Plasmodium falciparum, the protozoan parasite caus-
ing falciparum malaria, is undoubtedly highly versa-
tile when it comes to survival and defence strategies. 
Strategies adopted by the asexual blood stages of Plas-
modium range from unique pathways of nutrient 
uptake to immune evasion strategies and multiple 
drug resistance. Studying the survival strategies of 
Plasmodium could help us envisage strategies of tack-
ling one of the worst scourges of mankind. 
WHY would one want to study strategies adopted for  
survival by a parasite like Plasmodium falciparum? An 
analogy might help to appreciate the importance of sur-
vival strategies. A smart burglar studies his target house 
till he knows it like the back of his hand, before breaking 
into it. A successful parasite is somewhat like the smart 
burglar. It knows exactly what resources are available to 
it from the host, and accordingly adopts strategies either 
to modify the host or to make the most of it. Survival 
strategies are indispensable indeed, to the parasite, but 
why again would one want to study them? Extending the 
analogy a little further, to crack a tough case, a detective 
would need to put himself into the shoes of the burglar. 
We would do well, too, at controlling parasites and tack-
ling the diseases they cause, if we were to emulate the 
smart detective! 
Before going into the strategies adopted by it, it would 
be fruitful to have a look at the parasite. Plasmodium is  
a protozoan parasite classified under the phylum Api-
complexa which also includes parasites like Toxoplasma, 
Eimeria and Cryptosporidium, all of which are endowed 
with a specialized apical complex for host cell invasion. 
Four species of Plasmodium infect man – P. vivax, P. 
ovale, P. malariae and P. falciparum, among which P.
falciparum is by far the most virulent1. Malaria, the dis-
ease caused by Plasmodium continues to be the disease 
with the highest mortality rate, next only to tuberculosis. 
It is endemic to around 100 countries in the world. Appro-
ximately 500 million cases of malaria are reported every 
year, and around 3000 children die of malaria every day1. 
Emerging resistance to all currently prescribed drugs  
limits treatment of malaria today. Hence, the identifica-
tion of antimalarial drug targets is of critical importance. 
Studying the survival strategies of P. falciparum is there-
fore extremely relevant. 
A quick look at the lifecycle of this parasite (Figure 1) 
reveals a complex process involving two hosts – the ver-
tebrate host, man, and the invertebrate host (v ctor), the 
female Anopheles mosquito2. Infection in man begins 
with the bite of a female Anopheles mosquito harbouring 
sporozoites in its salivary gland. The sporozoites in the 
blood stream find their way to the liver and invade the 
hepatocytes within 30 min of being released by the mos-
quito. Asexual reproduction (exoerythrocytic schizo-
gony) in the liver releases merozoites, which are the first 
stage of the 48-h asexual reproduction cycle in the red 
blood cells (RBCs; erythrocytic schizogony). The blood 
stages constituting this cycle, studied by light and elec-
tron microscopy3, are the merozoite, the ring, the tropho-
zoite and the schizont which ruptures to release 
merozoites that invade fresh RBCs (Figure 1). The mero-
zoite, which is the only stage to b  briefly extracellular 
during invasion, and therefore of great immunological 
interest, is suitably armed with a bristly coat and an api-
cal complex comprising the rhoptries, dense granules and 
micronemes (required for RBC invasion). The ring, so 
called because of its signet ring-like appearance in light 
microscopy, is an actively feeding stage. So also is the 
trophozoite that differs only by its larger size and by the 
presence of cytostomes for end cytosis of the host cell 
stroma. The schizont is the asexually dividing stage. 
Tangential mitotic divisions along with an increase in the 
number of organelles and the formation of apical com-
plexes in the schizont result in the formation of a number 
of merozoites within the parasitophorous vacuole which 
envelops the parasite plasma membrane. Some of the 
merozoites that invade the RBCs do not go through the 
asexual reproduction cycle, but mature to male and  
female gametocytes which are picked up by the female 
Anopheles mosquito during a blood meal. Mature sporo-
zoites released from the oocyst following fertilization of 
the gametes in the midgut of the mosquito and meiosis, 
find their way to the salivary glands and are injected into 
a human host when the mosquito takes a blood meal, and 
thus the cycle continues. 
Survival strategies adopted by parasites vary with the 
habit of the parasite. An intracellular parasite has the  ‡For correspondence. (e-mail: surolia@mbu.iisc.ernet.in) 
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undoubtedly big advantage of not eliciting much of an  
immune response from the host, while the extracellular 
parasite scores over its intracellular co nterpart with rega d 
to tissue colonization and easy entry into and exit from a 
host. Common survival strategies adopted by parasites 
are those for attachment to host tissues, access to host 
nutrients and avoidance of the host defence system4. 
Strategies adopted by the asexual blood stages of P. 
falciparum include transport of macromolecules and ions 
across the RBC into the parasite – acc ss to host nutri-
ents; haemoglobin digestion and haem detoxification; 
novel metabolic pathways; immune evasion strategies 
and  multiple drug resistance. 
Among these, the former three are discussed in this  
review. Immune evasion strategies and multiple drug 
resistance have been the topics of several past reviews, 
and have not been covered here. 
Transport of macromolecules and ions across the 
RBC into the parasite – access to host nutrients 
P. falciparum is a rapidly growing parasite – ev ry 48 h, 
12 to 16 merozoites emerge out of a schizont. To fuel this 
phenomenal rate of growth, the parasite needs nutrients 
from outside the infected cell. The host RBC is metaboli-
cally inert and is not capable of transporting in sufficient 
quantity, at least some of the nutrients and ions which P. 
falciparum requires to satisfy its voracious appetite. The 
parasite would therefore need to increase the permea-
bility of the red cell membrane to nutrients and ions. The 
permeability of infected red cell membranes could theo-
retically be increased by the presence of activated native 
transporters or parasite-inserted channels in the red cell 
membrane, or by an increase in membrane fluidity 
brought about by the insertion, in the membrane, of para-
site-derived lipids or proteins which cause structural  
defects (Table 1). Evidence today points to two major 
types of trafficking pathways besides endocytosis of the 
host cell stroma into the parasite (Figure 2). 
Direct pathway 
This model is supported by evidence in favour of the 
presence of an aqueous parasitophorous duct connecting 
the parasitophorous vacuole to the external medium.  
Serum macromolecules can therefore be accessed by the 
parasite by passive diffusion into the parasitophorous 
vacuole through the parasitophorous duct, followed by 
endocytosis into the parasite. Evidence in favour of this 
duct comes from fluorescence microscopy studies using 
fluorescence dextrans and immunoglobins5. Though these 
initial studies evoked considerable controversy6,7, further 
evidence in the form of transmission electron microscopy 
has been reported recently8. Moreover, fragments of  
recombinant amino levulinic acid dehydratase added to 
the culture medium were shown to enter infected red c lls 
and inhibit P. falciparum growth9. Given the absence of 
endocytosis and other mechanisms for the impor  of these 
macromolecules, it is possible that the duct indeed exists. 
The bulk of the evidence available today, however, tilts 
the balance in favour of the sequential pathway. 
Sequential pathway 
The sequential model involves the transport of solutes 
from the serum, first across the red cell membrane and 
Table 1. Possible mechanisms to increase the permeability of the  
red cell membrane 
 
Protein-mediated 
· Activation of host transporters. 
· Insertion of parasite-derived transporters in host plasma membr ne. 
· Leaks resulting from structural defects in host membranes with 
parasite-inserted proteins. 
 
Lipid-mediated 
· Increased fluidization caused by parasite-inserted lipids in host 
membrane. 
 
 
Figure 1. Life cycle of Plasmodium falciparum in man and the inver-
tebrate vector, Anopheles, showing the sporozoites in the salivary 
glands of Anopheles and the asexual stages – merozoites, rings, tropho-
zoites and schizonts, and the sexual stages – m le and female gameto-
cytes in the red blood cells of man. 
 
 
 
Figure 2. Two models for the uptake of nutrients and ions by Plas-
modium – (1) direct pathway and (2) sequential pathway. The direct 
pathway makes use of the parasitophorous duct, which is continuous 
with the parasitophorous vacuole. The sequential pathway involves the 
passage of solutes sequentially through the protein channels on the red 
cell membrane (black), parasitophorous vacuolar membrane (green), 
and the parasite plasma membrane (blue). The endocytosis pathway (3) 
allows uptake into the food vacuole (FV) from the red cell cytosol.
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then across the parasitophorous vacuolar membrane  
(Figure 2). This model is supported by evidence in favour 
of the presence of voltage-dep ndent, anion-selective 
channels (however whether of host or of parasite origin is 
not known as yet) on the membrane of infected red cells 
demonstrated by tracer studies, and recently by whole 
cell conductance measurements10–12. Voltage-dependent 
channels have also been shown to be present on the para-
sitophorous vacuolar membrane by patch clamp experi-
ments13,14. Besides these components of the sequential 
pathway, a tubovesicular membrane network, which ex-
tends out of the parasitophorous vacuolar membr ne, has 
been demonstrated by Bodipy ceramide membrane stain-
ing as well as by Lucifer yellow accumulation experi-
ments in the parasite15. Lucifer yellow accumulation in 
the infected red cell was inhibited by PPMP, an inhibitor 
of the enzyme, sphingomyelin synthase, which is invol-
ved in the synthesis of the abundant sphingomyelin of the 
tubovesicular membrane network. The tubovesicular mem-
brane network could allow the parasite efficient access to 
nutrients. 
The solutes transported into the parasitophorous vacu-
ole by either of these models are taken up by the parasite 
with the help of solute-sp cific transporters present on 
the parasite plasma membrane10,16. Transporters specific 
to several amino acids, nucleotides and glucose are pre-
sent17. So also is a V-type ATPase that sets up a proton 
gradient allowing the inward transport of pantothenic 
acid and K+, and the extrusion of lactate and glutamate 
across the plasma membrane18,19. Additionally, Na+/H+ 
and Ca2+/H+ ion exchangers are present16. 
Protein trafficking 
How are the changes in the RBC transport properties 
brought about by P. falciparum? During the course of P. 
falciparum infection, the red cell membrane and cytosol 
as well as the parasitophorous vacuole are implanted with 
several proteins of parasite origin20,21, which probably  
are responsible for these changes, besides playing a role 
in cytoadherence and vessel occlusion, the characteristic 
pathologic condition of cerebral malaria. How do these 
proteins find their way across the parasite plasma mem-
brane and in the former case, across the parasitophorous 
vacuolar membrane too, to the red cell? In the abse ce of 
any endogenous transport machinery, export mechanisms 
must be engineered by the parasite. Two models, the one-
step model and the two-s ep model, have been put  
forward to explain this enigma22 (Figure 3). 
According to the one-st p model, the parasite cytosol 
has two types of transport-vesicles to traffic proteins to 
the parasitophorous vacuole and the red cell respectively. 
The first fuses with the parasite plasma membrane to  
release its protein contents into the parasitophorous vacu-
ole, and the second fuses with regions of the parasite 
plasma membrane which are closely juxtaposed to the 
parasitophorous vacuolar membrane, releasing its protein 
contents directly into the red cell cytosol22. H wever, no 
evidence for the presence of two types of vesicles has 
been reported so far. 
Ac ording to the two-step model, all parasite proteins 
to be exported outside the parasite are transported by 
vesicles, which fuse with the parasite plasma membrane, 
rel asing them into the parasitophorous vacuole. Proteins 
whos  destination is beyond the parasitophoous vacu le 
pass through the parasitophorous vacuolar membrane 
presumably with the help of chaperones in the parasito-
phorous vacuole, which keep these proteins in the un-
folded state. It is also possible that these proteins have 
very little conformation and hence can easily cross the 
membrane. Immunofluorescence microscopy and prote-
ase protection analyses done with parasite protein mark-
ers for each of the compartments of the infected red cell 
(aldolase for the parasite plasma membrane, SErine-Rich 
Protein (SERP) for the parasitophorous vacuole, and 
glycophorin-binding protein for the red cell cytosol) were 
in agreement with the two-s ep model22,23. 
Within the red cell cytosol itself, the temporal and spa-
tial nature of protein targeting by the parasite as shown 
by localization experiments, suggests multiple pathways 
of protein delivery, unique targeting signals and regula-
tion of secretory transport apparatus24–26. Though some 
parasite proteins which are exported do have ER (endo-
plasmic reticulum) signal sequences, and merozoite  
proteins that contain DBLs (Duffy Binding-Like) have 
canonical signal sequences for cotranslational ER recruit-
ment, many exported proteins do not have an N-terminal 
hydrophobic ER signal sequence, and signal sequences 
for yet others such as the VARs which are targe ed to the 
red cell membrane are yet to be elucidated27,28. GPI 
anchor , N-terminal transit peptide sequenc s a d other 
motifs play a role in protein trafficking to various loc-
tions within the parasite it elf27. 
With regard to the secretory transport apparatus, the 
ER has been indicated as part of the secretory pathway by 
electron microscopy as well as by experiments showing 
Brefeldin A-sensitivity of protein transport29,30. An un-
stacked Golgi lacking cisternae and glycosyl transferases 
and glycosidases, has been demonstrated by deconvolu-
tion microscopy and immunoelectron mic scopy, as also 
by the existence of Golgi marker proteins, sphingomyelin 
synthase, PfERD2 and Rabs1, 6 and 11 (refs 29, 31 and 
32). Besides these components of the secretory pathway 
wi hin the parasite, plasmodial homologues of the COPII 
proteins, Sar1p and Sec31p, as well as the homologue of 
N-ethyl maleimide-s nsitive factor (PfNSF), which are 
involved in secr tory vesicle exit from ER and fusion of 
s cretor  vesicles with their target membranes respec-
tively, have been localized to structures outside the para-
site in the erythrocyte cytoplasm, suggesting that the 
mal r a parasite exports components of its trafficking 
apparatus, thus establishing a vesicle-m diated traffick-
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ing pathway outside the boundaries of its own plasma 
membrane33–36. 
Besides the parasite-derived components of the secr-
tory pathway in the erythrocyte cytosol, the parasite also 
seems to recruit host machinery for the trafficking of its 
proteins. This is supported by studies on chaperones  
recruited during the transport of parasite-secre d cargo 
proteins to the erythrocyte plasma membrane37. None of 
the reported chaperones of parasite origin are present in 
the erythrocyte cytoplasm. The erythrocyte cytosol instead 
contains chaperones of the host (Hsp70, Hsp90, Hop60) 
which can be detected by hypotonic lysis and detergent 
solubilization experiments. Unlike their soluble nature  
in normal erythrocytes, host chaperones are recruited in 
membrane-bound, detergent-resistant complexes in infec-
ted cells, confirming their recruitment in the assembly of 
parasite proteins such as knob subunits (PfHRP1) at the 
erythrocyte surface. 
Besides host chaperones, there is also definitive evi-
dence that despite the absence of endocytosis, transmem-
b ane proteins in the host red cell membrane are recruited 
by the parasite and imported to the parasitophorous 
vacuolar membrane38. These are, again, mainly protein 
components of detergent-resistant membrane rafts in red 
cell membrane and are detected in rafts in the parasito-
phorous vacuolar membrane. Disruption of either ery-
throcyte or vacuolar rafts is detrimental to infection, 
suggesting that raft proteins and lipids are essential for 
the parasitization of the red cell. 
Haemoglobin digestion and haem detoxification 
Haemoglobin constitutes more than 90% of the total pro-
tein in a red cell. At 20% parasitaemia, during the tro-
phozoite stage, more than 60% of the host haemoglobin, 
approximately 140 g, in a red cell is digested by the para-
site. Besides amino acid uptake and d  novoamino acid 
synthesis in the parasite, haemoglobin digestion is a major 
source of amino acids (Figure 4). Haemoglobin is taken 
up by simple endocytosis of the host cell stroma during 
the ring stage of the parasite and with the help of special-
ized organelles known as cytostomes during the tropho-
zoite stage. The endocytotic vesicles empty their contents 
into the acidic food vacuole, the specialized lysosome-
like organelle of the parasite. The aspartic protease, 
plasmepsin I, initiates haemoglobin digestion by cleaving 
the highly conserved haemoglobin hinge region between 
the Phe33 and the Leu34 amino acids. This cleavage de-
stabilizes the globin molecule, making it suscep ible to 
further enzymatic action39. A recently discovered aspartic 
proteinase, plasmepsin IV from the human malaria para-
site P. falciparum is also able to hydrolyse human hae-
moglobin at a site known to be the essential primary 
cleavage site in the haemoglobin degradation pathway40. 
 
 
Figure 4. Haemoglobin digestion and haem metabolism in the food vacuole of Plasm dium. 
Endocytosed host haemoglobin is a source of amino acids for the parasite. Toxic haem is polymer-
ized to hemozoin within the food vacuole and reactive oxygen intermediates generated by oxidation 
of haem are detoxified by catalase and superoxide dismutase. 
 
 
Figure 3. Two models for the trafficking of parasite proteins to the 
red cell cytosol and the parasitophorous vacuole. In the one-step-
model, parasite proteins destined for the parasitophorou  vacuole and 
the RBC cytosol are transported by separate vesicles (1, 2). In the two-
step-model, (3), both classes of proteins are transported by vesicl s
into the parasitophorous vacuole. Proteins destined for the red cell 
cytosol are then transported via a second step through channels on the 
parasitophorous vacuolar membrane (PVM). PPM, Parasite plasma 
membrane; RBCM, Red blood cell membrane. 
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Three papain-family cysteine protease sequences have 
been identified in the P. falciparum genome, but the  
specific roles of their gene products and other plasmodial 
proteases in haemoglobin hydrolysis are uncertain41. Fal-
cipain 1, like plasmepsin, is capable of cleaving native 
haemoglobin, while falcipain 2 cleaves denatured haemo-
globin. Falcipain 2 and falcipain 3 are principally  
expressed by early trophozoites and appear to be located 
within the food vacuole, the site of haemoglobin hydro-
lysis. Both proteases require a reducing environment and 
acidic pH for optimal activity, and both prefer peptide 
substrates with leucine at the P(2) position. The prteases
differ, however, in that falcipain 3 u dergoes effi- 
cient processing to an active form only at acidic pH,  
is more active and stable at acidic pH, and has much 
lower specific activity against typical papain-family  
peptide substrates, but has greater activity against native 
haemoglobin. Thus, falcipain 3 is a second P. falci- 
parum haemoglobinase that is particularly suited for  
the hydrolysis of native haemoglobin in the acidic food 
vacuole42. 
Falcilysin cleaves polypeptides formed by the action of 
plasmepsin and falcipain43. The peptides formed by the 
action of all these enzymes are presumably transported to 
the parasite cytosol by the transporter Pfmdr-1, where they 
are digested by aminopeptidases44,45. Free haem spells 
potential disaster for membranes, and besides, the oxida-
tion of Fe2+ to Fe3+ generates an electron, which results in 
the release of free radicals like superoxide and H2O2. It 
is therefore imperative that haem is converted to a less 
toxic compound. Previous findings suggested that haem 
is converted to insoluble haemozoin (b-haematin) by a  
polymerization reaction46. Chemical analysis has shown 
that P. falciparum trophozoites contain approximately 
61% of the iron within parasitized erythrocytes, 92% of 
which is located within the food vacuole. 57Fe-Mössbauer 
spectroscopy and electron spectroscopic imaging show 
that haemozoin is the only detectable iron species in tro-
phozoites47. 
The polymerization to haemozoin is not a spontaneous 
reaction48, and neither is it an enzyme-catalysed reaction 
as considered earlier, since the reaction proceeds in the 
presence of proteases and at very high temperatures49,50. 
Evidence suggests that the polymerization is probably a 
physio-chemical, lipid-catalysed reaction in the infected 
cells51–54. Malaria parasite homogenate, lipid extracts, 
and an unsaturated fatty acid, linoleic acid have been 
shown to promote beta-haematin formation in vitro. The 
presence of ascorbic acid, reduced glutathione, sodium 
dithionite, beta-mercaptoethanol, dithiothreitol and super-
oxide dismutase, as also peroxidized lipid preparations and 
oxygen depletion i the reaction mixtures inhibit the 
lipid-catalysed beta-h ematin formation. b-free-radical 
chain reaction breakers such as p-aminophenol also inhi-
bit haematin formation. All this calls for an oxidative 
mechanism of lipid-mediated b-haematin formation, 
which may be mediated by the generation of some free-
radical intermediates of haem. 
Histidine-rich proteins are thought to play a role in 
polymerization55. Histidine-rich protein-2 (PfHRP2) not 
only binds up to 50 molecules of ferriprotoporphyrin 
(FePPIX), it also modulates the redox activity of FePPIX, 
imparting to the PfHRP2–FePPIX complex previously 
unrecognized antioxidant properties56. The free radicals 
generated from haem are taken care of by endcytos d 
host superoxide dismutase and, by catalase and gluta-
thione reductase, which are possibly of parasite origin57. 
 
Novel metabolic pathways in P. falciparum 
Metabolic pathways in a parasite, which often are the key 
to discovering peculiarities and idiosyncrasies that can be 
exploited in drug design, are intimately related to the 
niche inhabited by the parasite. 
The main source of energy for the rapidly growing 
P. falciparum is the glycolysis pathway58. The rate of  
energy generated by lactate fermentation following gly-
colysis can be as much as 100-fold compared to what  
can be obtained on oxidative phosphorylation. The para-
site has, thus, done away with the citric acid cycle, and 
the pyruvate generated by glycolysis is converted to lac-
tate, which is the end product of glycolysis in the para-
site. Moreover, unlike the host enzyme, there is no 
substrate inhibition of the enzyme LDH by pyruvate,  
facilitated perhaps by an insert on of five amino acids, 
which brings about a shift in the binding cleft of NADH 
to LDH observed in the crystal structure of the parasit  
LDH enzyme. This allows fast energy production to fuel 
the rapid rate of growth of the parasite inside the red cell. 
Enzymes of the glycolysis pathway in P. falciparum, in 
particular, triose phosphate isomerase, have been studied 
in great detail, and offer promise of therapeutic leads and 
insights into antimalari  drug design59,60. 
Reactive oxygen species (ROS) are a nightmare for 
any intracellular pathogen. The malarial parasite, how-
ever, has its own battery of defence tactics lined up 
against ROS. The parasite has its own hexose monophos-
phate shunt pathway, including the first enzyme G6PD, 
and glutamate dehydrogenase that generates NADPH, 
which it uses along with host reducing power to ward-off 
damage from the ROS generated by itself, the RBC as 
well as host immune cells61. ROS are generated in par-
ticular during oxidation of Fe2+ in haem to Fe3+. Super-
oxide generated during this process is dismutased to 
H2O2 by SOD, and H2O2 is reduced by catalase and glu-
tathione peroxidase. The oxidized glutathione formed 
during this process is reduced back to its original state by 
glutathione reductase at the expense of NADPH oxida-
tion. All these enzymes, i.e. SOD, catalase, glutathione 
peroxidase and glutathione reductase are produced by the 
parasite. The parasite SOD shows Mn/Fe SOD activities, 
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unlike the host Cu/Zn SOD that incidentally is also endo-
cytosed by the parasite, and is regarded a potential target 
for antimalarial chemotherapeutics. The glutathione  
reductase and thioredoxin reductase systems present two 
powerful ways of combating oxidative stress in the para-
site62. GSH, which is the major low-molecular-mass 
tripeptide thiol in most organisms, maintains a reduced 
intracellular environment and protects cellular compo-
nents from the damaging oxidation. GSH is synthesized 
by the action of two ATP-dependent enzymatic steps,  
in which gamma-glutamyl cysteine synthetase (gamma-
GCS) catalyses the ligation of glutamate and cysteine, 
and subsequently glutathione synthetase (GS) adds gly-
cine to the dipeptide. The synthesis of gamma-glutamyl 
cysteine has been demonstrated in the parasite using  
the specific gamma-GCS inhibitor, buthionine sulphoxi-
mine63. Genes for glutathione reductase (Pfgr1) and  
thioredoxin reductase (Pfgr2) have been identified. Thio-
redoxin reductase (TrxR) knockouts in P. falciparum are 
not viable, suggesting that TrxR is essential for P. f ci-
parum erythrocytic stages64. 
Nucleic acid metabolism is one area where differences 
exist between the pathways of P. falciparum and those of 
the human host. P. falciparum synthesizes purines by the 
salvage pathway65 and pyrimidines de novo, the reverse 
of the predominantly used pathways in the host cell 
(mammalian cells synthesize purines de ovoand either 
salvage or synthesize pyrimidines de novo), and are 
therefore of considerable interest from a phar cological 
point of view. The purine salvage pathway utilizes the 
plasmodial enzyme, HGPRT, adenyl succinate synthase 
and inosine dehydrogenase58,66. HGPRT catalyses the 
transfer of a phosphoribosyl moiety from hypoxanthine 
to inosinic acid. The low activity of this enzyme recov-
ered from cell lysates as well as the considerable homo-
logy with its human counterpart, make it an improbable 
drug target. The predominant precursor for salvage is 
hypoxanthine, formed during ATP catabolism. However, 
inosine formed from adenosine by adenosine deaminase 
or taken up from the host could also be the precursor. 
Both AMP and GMP can be formed from IMP by adenyl 
succinate synthase and adenyl succinate lyase, and IMP 
dehydrogenase and GMP synthase respectively. 
The enzymes, carbomoyl phosphate synthase, aspartate 
transcarbamylase, dihydroorotase, dihydoorotate dehydro-
genase, orotate phosphoribosyl transferase, and orotidine 
5¢-phosphate decarboxylase bring about pyrimidine syn-
thesis de novo. The pathway is similar to that in other 
eukaryotes, except that unlike in other eukaryotes, the 
first three enzymes are separate from one another58. The 
mitochondrial enzyme, dihydroorotate dehydrogenase, 
catalysing the single rdox reaction inthe pyrimidine  
de novo synthetic pathway, links electron transport in the 
mitochondrion with pyrimidine synthesis and is also the 
major supply of electrons for the mitochondrial electron 
transport chain. Dihydroorotate-dependent respiration is 
facilitated by the complex II (succinate-ubiquinone  
reductase/quinol-fumarate reductase) in the electron 
transport chain, which functions as a quinol-fumarate 
reduc ase58.
Folate, which is required for purine salvage and  
de novo biosynthesis of amino acids and pyrimidines, is 
synthesized either by the salvage or the de novo pathway 
in the parasite, unlike the host, which can only salvage 
folates67. 
While all these metabolic pathways do offer a few drug 
targets, the presence of an equivalent enzyme in the host 
hamprs the development of a good antimalarial without 
any effect on the host enzyme. The discovery of the 
green-algal-plastid-like organelle, the apicoplast in the 
para ite, however, offers new hope68. Going by simi-
larity, it is expected that the plastid be involv d in bio-
synthesis pathways such as those of fatty acids, aromatic 
amino acids and haem, and in fact, the type II fatty acid 
biosynthesis pathway69 nd the haem biosynthesis path-
way70 do exist in the parasite. 
The fatty acid biosynthesis pathway in the parasite is 
of great pharmacological interest, thanks to the host fatty 
acid biosynthesis pathway being of type I69, unlike that of 
the parasite which has a fatty acid synthase II system in 
which the subsequent reactions of the pathway are cata-
lysed by independent enzymes. This difference could be 
used in designing drugs against each of the independe t 
enzyme targets of the pathway. The metabolic pathway 
involves the enzymes malonyl transacetylase (Fab D), b-
k toacyl ACP synthase (Fab H, B/F), b-ketoacyl ACP 
reductase (Fab G), b-hydroxy acyl ACP dehydrase (Fab 
A/Z) and enoyl ACP reductase (Fab I). The inhibitors of 
the enzymes, enoyl ACP reductase and b-ketoacyl ACP 
synthase, i.e. triclosan and cerulenin are effective in kill-
ing the parasite in vitro as well as in vivo in P. berghei. 
Triclosan inhibition of b-enoyl ACP reductase has also 
been extensively characterized and promises to be an 
excellent antimalarial target71–73. 
P. falciparum is engaged in biosynthesis of glycero-
lipid  during its blood stages. An aquaglyceroporin 
(PfAQP) has been implicated in the transport of sugar 
lcohols and as expected, is expressed in blood-stage 
parasites throughout the development from rings through 
schizonts. It is also presumed to function in the protec-
tion from osmotic stress and in access to the serum gly-
cerol pool for ATP generation74. 
It does seem extremely paradoxical that living as it 
do s in a sea of haemoglobin, Plasmodium would have 
i s own haem biosynthesis pathway. The toxic nature of 
haem and the reactive oxygen intermediates released dur-
ing its oxidation, however, warrant the conversion of 
haem to the non-t xic haemozoin as mentioned earlier, 
hus making it imperative for Plasmodium to synthesize 
its own haem. Haem is required for incorporation into 
cytochromes and other haem-containing proteins, as well 
as for the reticulocyte lysate-like haem-dependent protein 
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synthesis occurring in the parasite. Evidence for de nov  
haem synthesis in P. falciparum was reported by Surolia 
and Padmanaban70 who demonstrated hat the precursors 
for ALA are glycine and succinate but not glutamate, as 
in animals, fungi and proteobacteria and unlike most bac-
teria and plants. Wilson et al.75 later identified a potential 
ALAS and suggested that the malarial enzyme ALAS is a 
mitochondrial protein like human ALAS. The genome 
sequencing projects for several species of Plasm dium 
suggest that malaria parasites may have a complete set of 
genes for haem biosynthesis. Bonday et al.76 and Padma-
naban and Rangarajan77 purified the second enzyme of 
the pathway, ALAD. Their immunolocalization experi-
ments led them to conclude, however, that the murine 
malarial parasite imports the host ALAD for haem bio-
synthesis. Recently, however, ALAD cDNA has been 
cloned and is shown to be functional by a complementa ion 
assay78. Sequence alignments suggest that the enzyme  
is closely related to the Zn2+-independent enzymes of 
plants. The gene further has a putative N- erminal plastid-
targeting sequence. This finding implicates a role for the 
observed contact between the two organelles in electron 
microscopy, the mitochondrion and the plastid, as being 
required for the transport of ALA from the first enzyme 
ALAS in the mitochondrion to the second enzyme ALAD 
in the plastid. With other enzymes of the pathway still to 
be studied, one cannot completely rule out the possibility 
of Plasmodium importing host enzymes for haem  
synthesis. 
The shikimate pathway, essential for the production f 
a plethora of aromatic compounds in bacteria, fungi and 
plants, also exists in apicomplexans, including P. falcipa-
rum79. Seven enzymes of the shikimate pathway catalyse 
sequential conversion of erythrose-4-phosphate and phos-
phoenol pyruvate to chorismate. Chorismate is the sub-
strate for subsequent reactions, which culminate in the 
production of folates, ubiquinone, naphthoquinones and the 
aromatic amino acids, tryptophan, tyrosine and phenyl-
alanine. The presence of the shikimate pathway explains 
the efficacy of the herbicide glyphosate, in prev nting the 
growth of the parasites. 
The P. falciparum apicoplast genome, measuring just 
about 35 kb, is much smaller than its plastid ancestor. 
This is mainly due to the transfer of the bulk of the plas-
tid genes to the nuclear genome, and the consequ nt 
transport of their encoded proteins to the plastid80.  
Nuclear encoded proteins headed towards the apicoplast 
are guided by their bipartite N-t rminal apicoplast-
targeting signals, containing a signal peptide that targets 
proteins to the secretory pathway, and an NKI-rich transit 
peptide with a net positive charge, that targets the protein 
across the multiple membranes of the apicoplast that is 
cleaved off by a stromal-processing peptidase homologue 
after import of the protein81–83. 
Retention of the relic genome of the plastid and its as 
yet ill-defined involvement in protein synthesis might be 
linked to an important housekeeping process, i.e. guard-
ing the type II fatty acid biosynthetic pathway from oxi-
dative damage. The parasite plastid does not divide by 
constriction like in typical plants, and pl stid-less par-
sites fail to thrive after invading a new cell, demonstra-
ting that the existence of the plastid is obligatory in the 
parasite84. 
R cent years have thus seen the discovery and detailed 
elucidation of several metabolic pathways in Plasmo-
dium. Getting to know the ins and outs of the infected red 
cell in the light of survival strategies adopted by P. falci-
parum should help us envisage ways of bringing under 
control, one of mankind’s greatest scourges. 
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